A former executive at companies like Syndax Pharmaceuticals, AstraZeneca and Pfizer has landed a new funding round for his latest venture.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results